To identify the cytochrome P450 (CYP) enzymes involved in the conversion of vesnarinone to it main primary metabolite OPC-18692 and to investigate the effect of CYP3A inhibition on the pharmacokinetics of vesnarinone in vivo.
|Number of pages||6|
|Journal||Clinical Pharmacology & Therapeutics|
|Publication status||Published - 1998|
|Event||98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics - Town and Country Hotel, San Diego, California, United States|
Duration: 5 Mar 1997 → 8 Mar 1997